Recombinant viral vector systems expressing exogenous feline paramyxovirus genes and vaccines made therefrom

A virus vector, paramyxovirus technology, applied in the field of vaccines, can solve problems such as toxicity recovery

Pending Publication Date: 2020-09-25
BOEHRINGER INGELHEIM VETMEDICA GMBH +1
View PDF53 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, as with some typical modified live viruses, occasionally virulence reversion may occur

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombinant viral vector systems expressing exogenous feline paramyxovirus genes and vaccines made therefrom
  • Recombinant viral vector systems expressing exogenous feline paramyxovirus genes and vaccines made therefrom
  • Recombinant viral vector systems expressing exogenous feline paramyxovirus genes and vaccines made therefrom

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0478] Example 1: Construction of vCP3025: ALVAC C5 / H6p synthetic Gordon H and vCP3029: ALVAC C3 / 42kLong synthetic Gordon M+C5 / H6p synthetic Gordon H (comprising SEQ ID NO: 49, SEQ ID NO: 50 and SEQ ID NO: 51; figure 2 , image 3 and Figure 4 )

[0479] Purpose: To generate two ALVAC constructs: one with a single insert and one with a double insert. The haploid construct expresses codon-optimized GordonH in the C5 insertion locus under the control of the H6 promoter. The double construct expresses codon-optimized Gordon H in the C5 insertion locus under the control of the H6 promoter and codon-optimized Gordon M in the C3 insertion locus under the control of the 42klong promoter.

[0480] Genes: Synthetic Gordon H; Synthetic Gordon M

[0481] General restructuring information:

[0482] A. Parental virus: the ALVAC derived from the later generation is basically the same virus as the parental ALVAC ATCCVR-2547 except for the subculture level; titer=1.5×10 10 pfu / mL

[...

example 2

[0560] Example 2: Vaccination example (vCP3025-Gordon H; comprising SEQ ID NO: 49; figure 2 )

[0561] At SD0 and SD21, a titer of approximately 1×10 was administered to a group of 8 cats (Group 1). 8 TCID50 / mL, ALVAC-Gordon H vector vaccine with a total dose of 1 mL. This dose is expected to deliver a sufficient amount of vaccine virus to promote an immune response against the selected antigen (FaPV-2 hemagglutinin). A negative control group (group 3) was vaccinated with an irrelevant ALVAC vector construct (ie ALVAC rabies). Animals were blood sampled at SD0, SD21 and SD 42 and humoral immune responses were measured by specific ELISA, immunofluorescence assay (IFA) and / or virus / serum neutralization test (VNT / SNT) (Example 4). At SD42, animals in the respective groups were vaccinated intravenously (IV) with the challenge virus (Example 5) as described below, and the given infection parameters (viremia, shedding, virus distribution) were additionally measured.

example 3

[0562] Example 3: Vaccination example (vCP3029-Gordon H+Gordon M; comprising SEQ ID NO:50+SEQ ID NO:51; image 3 + Figure 4 )

[0563] At SD0 and SD21, a titer of approximately 1×10 was administered to a group of 8 cats (Group 2). 8TCID50 / mL, ALVAC-Gordon H+M vector vaccine with a total dose of 1 mL. This dose is expected to deliver sufficient amounts of vaccine virus to promote an immune response against the selected antigens (FaPV-2 hemagglutinin and matrix protein). A negative control group (group 3) was vaccinated with an irrelevant ALVAC vector construct (ie ALVAC rabies). Animals were blood sampled at SD0, SD21 and SD 42 and humoral immune responses were measured by specific ELISA, immunofluorescence assay (IFA) and / or virus / serum neutralization test (VNT / SNT) (Example 4). At SD42, animals in separate groups were inoculated intravenously (IV) with challenge virus as described below (Example 5) and the given infection parameters (viremia, shedding, virus distribution...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to exogenous feline paramyxovirus genes, which are expressed from recombinant viral vector systems.

Description

[0001] sequence listing [0002] This application contains a Sequence Listing pursuant to 37 C.F.R. 1.821-1.825. The Sequence Listing accompanying this application is hereby incorporated by reference in its entirety. technical field [0003] The present invention is in the field of (vector) vaccines, and in particular to exogenous feline paramyxovirus genes expressed by recombinant viral vector systems. Furthermore, the present invention relates to feline paramyxovirus vaccines based on recombinant viral vectors. Background technique [0004] feline paramyxovirus [0005] Paramyxoviruses are enveloped antisense single-stranded RNA [(-)ssRNA] viruses that have been associated with various infectious diseases in humans and animals. There are two subfamilies of Paramyxovirinae - Paramyxovirinae and Pneumovirinae, and within the subfamily Paramyxovirinae there are at least five genera, namely Respirovirus, Rubulavirus, Morbillivirus, Henipavirus and Avulavirus. Examples of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N15/863C12N5/16A61K39/155
CPCA61K39/12A61K2039/5254A61K2039/5256C12N15/86C12N2710/24043C12N2760/18034C12N2760/18434C12N7/00C07K14/005A61P31/14
Inventor H·普莱V·尼科林A·J·德斯密特T·梅巴次翁
Owner BOEHRINGER INGELHEIM VETMEDICA GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap